NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase, CelleRx, and DERMAdoctor. The company was founded by Ramin Najafi on January 19, 2000 and is headquartered in Emeryville, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NovaBay Pharmaceuticals reports strong Q2 performance amidst market expansion

NovaBay Pharmaceuticals demonstrated strong performance in Q2 2024, driven by growth in eyecare products and improved gross margin.
While facing challenges such as net losses and low cash reserves, the company is focused on strategic transactions and market opportunities.
With a clear focus on the U.S. dry eye market and sales optimization, NovaBay is poised for continued growth and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase, CelleRx, and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three months ended March 31, 2022 and provides a business update. Financial results for the first quarter of 2022 include the operations of the DERMAdoctor business, which was acquired on November 5, 2021. “Total sales grew 46% during the first quarter and Avenova Spray unit sales increased 15% with record-high unit sales through the over-the-counter (OTC) channel,” said Ju

NovaBay Pharmaceuticals Reports First Quarter 2022 Financial Results

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces the expansion of its top-selling Kakadu C and Calm Cool + Corrected product lines with the introduction of next-generation products that are uniquely formulated with anti-aging ingredients to help reduce the appearance of wrinkles, fine lines, pores and discoloration. Kak

NovaBay Pharmaceuticals Expands Top-Selling DERMAdoctor Kakadu C and Calm Cool + Corrected Collections with New Anti-Aging Formulations

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three months ended March 31, 2022 after market close on Thursday, May 12, 2022 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time:   Thursday, May 12, 4:30 p.m. ET / 1:30 p.m. PT       Pre-Registration:   Participants can pre-register for the conference call here:     Callers who pre-register w

NovaBay Pharmaceuticals to Hold First Quarter 2022 Conference Call on May 12

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces that Chief Product Officer Audrey Kunin, MD will return to the QVC network as a live on-air guest to discuss DERMAdoctor's problem-solving eczema treatment. The revolutionary Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm will be featured on “Get Rea

NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin Returns to QVC® to Discuss DERMAdoctor's Eczema Treatment

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces the launch of Hydrating Cleansing Oil as the newest product under the DERMAdoctor Calm Cool + Corrected brand. Hydrating Cleansing Oil is a soap-free, pH-balanced cleanser that moisturizes and removes makeup while keeping skin hydrated. It was created by Audrey Kunin, MD,

NovaBay Pharmaceuticals Introduces Hydrating Cleansing Oil to its DERMAdoctor Calm Cool + Corrected Product Line

NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q4 2021 Results - Earnings Call Transcript

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and 12 months ended December 31, 2021 and provides a business update. Financial results include the operations of the acquired DERMAdoctor business beginning November 5, 2021. “NovaBay closed out an eventful year on a high note with fourth quarter net product revenue increasing 40% over the prior-year period on record Avenova spray unit sales,” said Justin Hall, NovaB

NovaBay Pharmaceuticals Reports 2021 Fourth Quarter and Full Year Financial Results

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and 12 months ended December 31, 2021 after market close on Tuesday, March 29, 2022 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Tuesday, March 29, 4:30 p.m. ET / 1:30 p.m. PT     Pre-Registration: Participants can pre-register for the conference call here:       Callers who pre-re

NovaBay Pharmaceuticals to Hold 2021 Fourth Quarter and Full Year Conference Call on March 29

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces the launch of Moisture Recovery HA Serum as the newest expansion to the Calm Cool + Corrected product line. Created by Audrey Kunin, MD, NovaBay's Chief Product Officer and a board-certified dermatologist, Moisture Recovery HA Serum is an innovative formulation of hyaluro

DERMAdoctor Launches New HA Serum to Expand Calm Cool + Corrected Product Line

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces that Chief Product Officer Audrey Kunin, MD will present DERMAdoctor's problem-solving eczema treatment as a live on-air guest on the QVC network. The revolutionary Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm will be featured on “Cheers! to Shoppi

NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Present DERMAdoctor Eczema Treatment as QVC® On-Air Guest

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality, scientifically formulated eyecare and skincare products, announces the engagement of one of China's leading marketing firms for omnichannel integrated marketing and branding services of DERMAdoctor skincare products in China. NovaBay's new marketing partner will also manage DERMAdoctor's online flagship store on Tmall.com, the leading business-to-consu

NovaBay Pharmaceuticals Engages Leading Chinese Marketing Firm to Drive Consumer Sales of DERMAdoctor Skincare Products in China

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focused on developing and commercializing high-quality, scientifically formulated products for the eyecare and skincare markets, announces the appointments of Audrey Kunin, M.D. and Julie Garlikov to the NovaBay Board of Directors. Dr. Kunin is a recognized leader in the skincare product industry and has served as NovaBay's Chief Product Officer since its acquisition in November 20

NovaBay Pharmaceuticals Announces Changes to Its Board of Directors

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $NBY #KN95_masks--NovaBay Pharmaceuticals donates 2.5 million KN95 protective masks.

NovaBay Pharmaceuticals to Donate 2.5 Million KN95 Masks

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $NBY #Avenova--NovaBay Pharmaceuticals launches Avenova Lubricating Eye Drops for the immediate relief of dry eye symptoms.

NovaBay Pharmaceuticals Expands Its Eyecare Product Portfolio With the Launch of Lubricating Eye Drops for the Immediate Relief of Dry Eye Symptoms

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focused on developing and commercializing scientifically formulated and clinically proven consumer products for the eyecare and skincare markets, announces that management will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022. A webcast of the NovaBay presentation will be available on the Events page of the company websi

NovaBay Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $NBY #Avenova--NovaBay Pharmaceuticals adjourns it Special Meeting of Stockholders until January 14, 2022

NovaBay Pharmaceuticals Holds Special Meeting of Stockholders

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $NBY #DERMAdoctor--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focused on developing and commercializing high-quality, scientifically formulated products for the eyecare and skincare markets, announces that DERMAdoctor's Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm has received the National Eczema Association (NEA) Seal of Acceptance™. The NEA Seal is granted in recognition of products that meet the NEA's

DERMAdoctor's Calm Cool + Corrected Eczema Balm Receives National Eczema Association Seal of Acceptance

ARC Document Solutions

Katapult Holdings

Does Insider Buying Mean A Bullish Outlook For These Penny Stocks? The post 3 Hot Penny Stocks To Buy In December According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Hot Penny Stocks To Buy In December According To Insiders

Chembio Diagnostics

Geovax Labs

iBio

Oragenics

SINTX Technologies Inc

XpresSpa Group

Hot penny stocks to watch as new virus fears emerge on Black Friday. The post Hot Penny Stocks To Buy?

Hot Penny Stocks To Buy? 7 To Watch As African Variant Shakes Markets

NovaBay Pharmaceuticals' (NBY) CEO Justin Hall on Q3 2021 Results - Earnings Call Transcript

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2021 and provides a business update. “This has been a great year for NovaBay. Avenova revenue has increased by 16% over the same period last year and we've cut our net loss per share in half. Unit sales have reached an all-time high as more people are using Avenova than ever before. Most importantly, with the closing of the DERMAdoc

NovaBay Pharmaceuticals Reports Third Quarter 2021 Financial Results

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $NBY #DERMAdoctor--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces the closing of the previously announced acquisition of DERMAdoctor, LLC. The Company also announced that it will report financial results for the third quarter 2021 on Thursday November 11, 2021 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. “Now that we have officially closed on the acquisition, it is time to start realizing synergies and growi

NovaBay Pharmaceuticals Closes DERMAdoctor Acquisition

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $NBY #DERMAdoctor--NovaBay completes $15 million financing and expects to complete acquisition of DERMAdoctor, LLC on November 5, 2021.

NovaBay Pharmaceuticals Closes $15.0 Million Private Placement

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $NBY #Avenova--NovaBay Pharmaceuticals announces pricing of $15 million private placement to fund acquisition of DERMAdoctor, LLC.

NovaBay Pharmaceuticals Announces Pricing of $15.0 Million Private Placement

NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on DERMAdoctor Acquisition - Conference Call Transcript

News for NovaBay Pharmaceuticals Stock (NBY)